MedTrace Logo

52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02120027 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 558

Last updated 2017-03-03

Study results available
· View outcomes & findings →

Summary

Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea. This trial aims at the evaluation of the efficacy and safety of oral ibodutant 10 mg once daily as compared to placebo in women with IBS-D over a 24-week treatment period.

Conditions

  • Irritable Bowel Syndrome With Diarrhea

Interventions

DRUG

Ibodutant 10 mg

Oral tablet, to be given once daily.

DRUG

Placebo

Oral tablet (identical in appearance and weight to ibodutant tablets) to be given once daily.

Sponsors & Collaborators

  • Menarini Group

    lead INDUSTRY

Principal Investigators

  • Jan Tack, Professor · Department of Gastroenterology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium

  • Lin Chang, Professor · Digestive Health and Nutrition Clinic. University of California, Los Angeles, CA, USA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • United States
  • Czechia
  • Germany
  • Hungary
  • Latvia
  • Poland
  • Slovakia
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02120027 on ClinicalTrials.gov